Description
Pharmaceutical grade lactose is used as a filler in the manufacturing of pharmaceutical tablets and capsules. The global pharmaceutical grade lactose exhibits a potential growth due to various factors such as increasing awareness about the use of pharmaceutical grade lactose and rising number of approvals from government bodies to use pharmaceutical grade lactose as an excipient, drug formulation coupled with nanotechnology, efficient compatibility with active ingredients and other excipients, and increasing healthcare expenditure. Furthermore, lactose is also used as an inactive ingredient in the Estradiol drug. However, stringent government regulations restrain the growth of the market.
The pharmaceutical grade lactose market is segmented on the basis of type and application.
On the basis of type, the market is segmented into crystalline monohydrate lactose, inhalation lactose, granulated lactose, spray-dried lactose, and others. Crystalline monohydrate lactose is further segmented into α-Lactose monohydrate and β-Lactose (anhydrous lactose). Sub-segmentation of α-Lactose monohydrate includes milled and sieved. Inhalation lactose is further segmented into sieved and milled. Crystalline monohydrate lactose dominates the pharmaceutical grade lactose with a share of 31.02% as compared to other types.
On the basis of application, the market is classified into tablets manufacturing, capsule manufacturing, and others. Tablets manufacturing is further classified into direct compression, wet granulation, and dry granulation. Capsule manufacturing is further classified into capsules, sachets, and others.
Key Players
The leading market players in the global pharmaceutical grade lactose market include BASF SE, Merck KGaA, Kerry Inc. DFE Pharma, Meggle, Armor Pharma, ALPAVIT, BASF SE, Sigma-Aldrich Corporation, Novartis AG, Bayer AG, GlaxoSmithKline plc, AstraZeneca plc, Abbott Laboratories, and others.
Study Objectives of the Pharmaceutical Grade Lactose Market
• To provide insights into factors influencing and affecting the market growth
• To provide historical and forecast revenues of market segments and sub-segments with respect to regional- and country-level markets
• To provide historical and forecast revenue of market segments based on types, products, applications, end-users, and its sub-segments.
• To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market.
Target Audience
• Pharmaceutical Companies
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities
• Medical Research Laboratories
• Market Research and Consulting Service Providers
• Potential Investors
Key Finding
• The pharmaceutical grade lactose market is expected to reach USD 229.48 million by 2023 at a CAGR of 4.1%.
• On the basis of application, the tablets manufacturing market is expected to command the largest market share of 52.1% over the review period, and it is also expected to grow at the fastest CAGR of 4.3% during the forecast period, 2017–2023
• Europe holds the largest share of the pharmaceutical grade lactose market and is expected to reach USD 94.289 million by 2023
• Asia Pacific is the fastest growing market, which is expected to grow at a CAGR of 4.4% over 2017–2023
Country-Level Analysis
• Americas
• North America
o U.S.
o Canada
• Latin America
• Europe
• Western Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Rest of Western Europe
• Eastern Europe
• Asia Pacific
• Japan
• China
• India
• Republic of Korea
• Rest of Asia Pacific
• Middle East & Africa
• Middle East
• Africa
Table of Contents:
1 Report Prologue
2 Market Introduction
2.1 Introduction
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
3 Research Methodology
3.1 Primary Research Methodology
3.2 Secondary Research Methodology
3.3 Market Share Analysis
3.4 Trade Analysis
3.5 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing demand for dry powder inhalers (DPI) products (Impact Weightage: 30%)
4.2.2 Compatibility with active ingredients and other excipients (Impact Weightage: 15%)
4.2.3 Approval from government bodies (Impact Weightage: 25%)
4.2.4 Drug formulation coupled with nanotechnology will boost the growth of pharmaceutical grade lactose market (Impact Weightage: 30%)
4.3 Restrains
4.3.1 Lactose-induced problems (Impact Weightage: 40%)
4.3.2 Stringent government regulations (Impact Weightage: 30%)
4.3.3 Lack compatibility with amine based drugs (Impact Weightage: 30%)
4.4 Opportunity
4.5 Mega Trends
4.5.1 Using lactose as excipient in nanotechnology-based drug formulations
4.6 Macroeconomic Indicators
4.7 Technology Trends & Assessment
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 R&D
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-sales Monitoring
5.2 Porters Five Forces Model
5.2.1 Bargaining power of suppliers (Medium to High)
5.2.2 Bargaining Power of Buyers (low to medium)
5.2.3 Threat of New Entrants (low to medium)
5.2.4 Threat of Substitutes (High)
5.2.5 Intensity of Rivalry (Medium)
5.3 Demand & Supply: Gap Analysis
5.3.1 Pricing Analysis
5.3.2 Investment Opportunity Analysis
6 Pharmaceutical Grade Lactose Market, by Type
6.1 Introduction
6.2 Crystalline Monohydrate Lactose
6.3 Inhalation Lactose
6.4 Granulated Lactose
6.5 Spray Dried Lactose
7 Global Pharmaceutical Grade Lactose Market, by Application
7.1 Introduction
7.2 Tablets Manufacturing
7.3 Capsule Manufacturing
8 Global Pharmaceutical Grade Lactose Market, by Region
8.1 Introduction
8.2 Europe
8.2.1 Western Europe
8.2.1.1 Germany
8.2.1.2 France
8.2.1.3 U.K.
8.2.1.4 Italy
8.2.1.5 Spain
8.2.1.6 Rest of Western Europe
8.2.2 Eastern Europe
8.3 Asia Pacific
8.3.1 Japan
8.3.2 China
8.3.3 India
8.3.4 Republic of Korea
8.3.5 Australia
8.3.6 Rest of Asia Pacific
8.4 Americas
8.4.1 North America
8.4.1.1 U.S.
8.4.1.2 Canada
8.4.2 South America
8.5 Middle East & Africa
8.5.1 Middle East
8.5.2 Africa
9 Company Landscape
9.1 Company Share Analysis
9.2 Competitive Landscape
10 Company Profiles
10.1 BASF SE
10.1.1 Company Overview
10.1.2 Financials
10.1.3 Products
10.1.4 Strategy
10.1.5 Key Developments
10.2 Merck KGaA
10.2.1 Company Overview
10.2.2 Financials
10.2.3 Products
10.2.4 Strategy
10.2.5 Key Developments
10.3 Kerry Inc.
10.3.1 Company Overview
10.3.2 Financials
10.3.3 Products
10.3.4 Strategy
10.3.5 Key Developments
10.4 DFE Pharma
10.4.1 Company Overview
10.4.2 Financials
10.4.3 Products
10.4.4 Strategy
10.4.5 Key Developments
10.5 Meggle
10.5.1 Company Overview
10.5.2 Financials
10.5.3 Products
10.5.4 Strategy
10.5.5 Key Developments
10.6 Armor Pharma
10.6.1 Company Overview
10.6.2 Financials
10.6.3 Products
10.6.4 Strategy
10.6.5 Key Developments
10.7 ALPAVIT
10.7.1 Company Overview
10.7.2 Financials
10.7.3 Products
10.7.4 Strategy
10.7.5 Key Developments
11 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO’s view point
11.2 Key Companies to Watch
12 Appendix
12.1 Discussion Blue Print
